Literature DB >> 2247765

Distribution of bronchoalveolar cells and fibronectin levels in bronchoalveolar lavage fluids from patients with lung disorders.

B Nakstad1, N P Boye, T Lyberg.   

Abstract

Differential cell counts and fibronectin levels were recorded in bronchoalveolar lavage fluids (BALF) from patients with lung cancer, idiopathic pulmonary fibrosis (IPF), sarcoidosis, pneumonia, acquired immunodeficiency syndrome (AIDS), and chronic obstructive lung disease (COLD). In all groups fibronectin levels were significantly higher than in the control group; patients with sarcoidosis had a six-fold higher fibronectin level (mean values), AIDS 5.4-fold, pneumonia 4.4-fold, lung cancer, IPF and COLD 2.4-3.0-fold. In control smokers the fibronectin level was significantly higher compared to healthy nonsmokers (p less than 0.002). The increased fibronectin levels could not be explained by contamination of BALF with blood or leakage of plasma proteins. Thus, increased fibronectin levels probably reflect local (e.g. macrophage/fibroblast) synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2247765     DOI: 10.3109/00365519009089175

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

1.  alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer.

Authors:  Jesse Roman; Jeffrey D Ritzenthaler; Sussane Roser-Page; XiaoJuan Sun; ShouWei Han
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

2.  Nicotine stimulates collagen type I expression in lung via α7 nicotinic acetylcholine receptors.

Authors:  Glenn W Vicary; Jeffrey D Ritzenthaler; Tanmay S Panchabhai; Edilson Torres-González; Jesse Roman
Journal:  Respir Res       Date:  2017-06-02

Review 3.  Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases.

Authors:  Kaj E C Blokland; Simon D Pouwels; Michael Schuliga; Darryl A Knight; Janette K Burgess
Journal:  Clin Sci (Lond)       Date:  2020-10-30       Impact factor: 6.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.